Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. Get Fractyl Health alerts:Get Our Latest Research Report on Fractyl HealthFractyl Health Price PerformanceNASDAQ GUTS opened at $0.69 on Thursday. Fractyl Health has a fifty-two week low of $0.38 and a fifty-two week high of $2.44. Fractyl Health Company Profile(Get Free Report)Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Recommended StoriesReceive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.